Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial

Summary

This is a double-blind, placebo-controlled, parallel group study designed to assess the tolerability and efficacy of fsCBD and bsCBD, compared to a placebo control, to improve cognition and traumatic brain injury-related symptoms. If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.

Timeline

Start

2023-04-11

Primary completion

2025-07-07

Completion

2025-07-07

Drugs

Indications